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Abstract
CTLA-4 encodes cytotoxic T lymphocyte-associated antigen-4,
a cell-surface molecule providing a negative signal for T-cell
activation. CTLA-4 gene polymorphisms have been widely
studied in connection with genetic susceptibility to various
autoimmune diseases, but studies have led to contradictory
results in different populations. This case-control study sought
to investigate whether CTLA-4 CT60 and/or +49A/G
polymorphisms were involved in the genetic predisposition to
primary Sjögren syndrome (pSS). We analysed CTLA-4 CT60
and +49A/G polymorphisms in a first cohort of 142 patients
with pSS (cohort 1) and 241 controls, all of Caucasian origin. A
replication study was performed on a second cohort of 139
patients with pSS (cohort 2). In cohort 1, the CTLA-4 +49A/
G*A allele was found on 73% of chromosomes in patients with
pSS, compared with 66% in controls (p = 0.036; odds ratio
(OR) 1.41, 95% confidence interval (CI) 1.02 to 1.95). No
difference in CTLA-4 CT60 allelic or genotypic distribution was
observed between patients (n = 142) and controls (n = 241). In
the replication cohort, the CTLA-4 +49A/G*A allele was found
on 62% of chromosomes in patients with pSS, compared with
66% in controls (p = 0.30; OR 0.85, 95% CI 0.63 to 1.16).
Thus, the CTLA-4 +49A/G*A allele excess among patients from
cohort 1 was counterbalanced by its under-representation in
cohort 2. When the results from the patients in both cohorts
were pooled (n = 281), there was no difference in CTLA-4
+49A/G allelic or genotypic distribution in comparison with
controls. Our results demonstrate a lack of association between
CTLA-4 CT60 or +49A/G polymorphisms and pSS. Premature
conclusions might have been made if a replication study had not
been performed. These results illustrate the importance of case-
control studies performed on a large number of patients. In fact,
sampling bias may account for some contradictory results
previously reported for CTLA-4 association studies in
autoimmune diseases.
Introduction
Polymorphisms in CTLA-4, the gene encoding cytotoxic T lym-
phocyte-associated antigen-4, have been widely studied in
connection with genetic susceptibility to various autoimmune
diseases [1], but studies have led to contradictory results in
different populations.
Among CTLA-4 gene polymorphisms, a G to A transition at
position 49 (+49A/G) of exon 1 leads to an alanine to threo-
nine amino acid substitution at codon 17 in the leader peptide
(A17T), and a C to T transition at position 60 (CT60) is located
within the 3'-untranslated region [2]. The G allele of +49A/G
has been associated with a predisposition to manyPage 1 of 3
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CI = confidence interval; CTLA-4 = cytotoxic T lymphocyte-associated antigen-4; OR = odds ratio; pSS = primary Sjögren syndrome; SNP = single 
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Arthritis Research & Therapy    Vol 9 No 2    Gottenberg et al.autoimmune diseases (reviewed in [1]). Both polymorphisms
are in linkage disequilibrium, which warrants haplotype analy-
sis in studies of CTLA-4 polymorphisms. The CT60 G allele
has been reported to increase susceptibility to several autoim-
mune diseases [2], and a functional approach provided evi-
dence for lower mRNA levels associated with the CT60 G
allele [2].
Downie-Doyle and colleagues have recently reported a signif-
icant association of the CTLA-4 +49A/G*A allele and of the
CTLA-4 +49A/G*A allele carrier haplotypes with primary Sjö-
gren syndrome (pSS), especially in patients with anti-SSA or
anti-SSB antibodies, in a study including 111 Australian
patients with pSS and 156 controls [3].
The aim of our study was to investigate in a large case-control
study whether CTLA-4 CT60 and/or +49A/G SNPs were
involved in genetic predisposition to pSS in French patients.
Materials and methods
Patients
A first cohort of 142 unrelated patients with pSS diagnosed in
accordance with the European American consensus group
criteria [4] (37% without autoantibodies, 30% with anti-SSA
antibodies only, and 33% with both anti-SSA and anti-SSB
antibodies) and 241 healthy blood donors were genotyped for
CTLA-4 CT60 and +49A/G polymorphisms. A second inde-
pendent cohort of 139 patients with pSS was further geno-
typed for CTLA-4 +49A/G polymorphisms in a replication
study. The geographical origin and the clinico-biological char-
acteristics of the patients in this second cohort were the same
as those in the first. In this second cohort, 27% of patients
were anti-SSA and anti-SSB negative, 35% had anti-SSA only
and 38% had both anti-SSA and anti-SSB. All patients and
controls were Caucasians and provided informed consent.
Genotyping
After the isolation of genomic DNA from peripheral blood
mononuclear cells, CTLA-4 CT60 and +49A/G polymor-
phisms were genotyped by restriction fragment length poly-
morphism with the use of BbvI (+49A/G) and NlaIII (CT60).
Statistical analysis
Allelic and genotypic frequencies of CTLA-4 CT60 and +49A/
G polymorphisms were compared between patients and con-
trols by using a two-sided χ2 test. All genotyped SNPs were in
Hardy–Weinberg equilibrium. CTLA-4 (+49A/G or CT60)
haplotypes, constructed with the PHASE program, were also
examined for association with pSS. P < 0.05 was considered
significant.
Results
In the first cohort of patients with pSS, the A allele of the
CTLA-4 +49A/G polymorphism was found on 73% of chro-
mosomes in patients with pSS, in comparison with 66% in
controls (p = 0.036, odds ratio (OR) 1.41, 95% confidence
interval (CI) 1.02 to 1.95; Table 1). No significant difference in
CTLA-4 +49A/G*A allele frequencies was observed among
subgroups of patients according to their anti-SSB and/or anti-
SSA status (Table 1). No difference in CTLA-4 CT60 allelic or
genotypic distribution was observed between patients (n =
142) and controls (n = 241). CTLA-4 (+49A/G or CT60) hap-
lotype distribution mirrored the CTLA-4 +49A/G*A allele
excess among patients with pSS (A/A 48%, A/G 26%, G/G
26%, G/A 0.4%; in comparison with A/A 45%, A/G 21%, G/
G 34% among controls), leading to an excess of +49A/G*A
allele carrier haplotypes among patients (p = 0.03, OR 1.41,
95% CI 1.02 to 1.95).
To avoid the possibility of a false positive association of CTLA-
4 +49A/G*A with pSS as a result of the somewhat small sam-
Table 1
Allellic frequencies of CTLA-4 49A/G polymorphism among patient controls
CTLA-4+49A/G Allele frequencies p Odds ratio (95% CI)
pSS SSA+ and SSB+ SSA+ only Ac+ Ac0 Controls (n = 241)
Cohort 1 n = 142 n = 47 n = 43 n = 90 n = 52 pSS vs controls
A (Thr) 208 (73) 68 (72) 61 (71) 129 (72) 79 (76) 318 (66) 0.036 1.41 (1.02–1.95)
G (Ala) 76 (27) 26 (28) 25 (29) 51 (28) 25 (24) 164 (34) 0.036 0.70 (0.51–0.98)
Cohort 2 n = 139 n = 52 n = 49 n = 101 n = 38 Controls (n = 241)
A (Thr) 173 (62) 59 (57) 66 (67) 125 (62) 48 (63) 318 (66) NS 0.85 (0.62–1.15)
G (Ala) 105 (38) 45 (43) 32 (33) 77 (38) 28 (37) 164 (34) NS 1.17 (0.86–1.60)
Total n = 281 n = 99 n = 92 n = 191 n = 90 Controls (n = 241)
A (Thr) 381 (68) 127 (64) 127 (69) 254 (66) 127 (71) 318 (66) NS 1.08 (0.84–1.40)
G (Ala) 181 (32) 71 (36) 57 (31) 128 (34) 53 (29) 164 (34) NS 0.92 (0.71–1.19)
Numbers in parentheses are percentages. pSS, primary Sjögren syndrome; Ac+, presence of anti SSB and/or anti-SSA; Ac0, absence of anti-
SSA or anti-SSB antibody; CI, confidence interval; NS, not significant.Page 2 of 3
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G*A allele has been only marginally associated with autoim-
mune diseases compared with the CTLA-4 +49A/G*G allele
[1], we performed a replication study on a second independ-
ent cohort of 139 patients with pSS. In this second cohort, the
CTLA-4 +49A/G*A allele was found on 62% of chromosomes
in patients with pSS, compared with 66% in controls (p =
0.30; OR 0.85, 95% CI 0.63 to 1.16; Table 1). Thus, the
CTLA-4 +49A/G*A allele excess among patients with pSS
from the first cohort was counterbalanced by its under-repre-
sentation in the second cohort. When the results from the
patients in both cohorts were pooled (n = 281), there was no
difference in CTLA-4 +49A/G polymorphism allelic or geno-
typic distribution in comparison with controls (p = 0.53, OR
1.09, 95% CI 0.84 to 1.4; Table 1). The sex ratios among
patients (0.97) and controls (0.06) were different. We there-
fore investigated CTLA-4 +49A/G polymorphism genotypic
distribution among males and females in the control group and
found that it was not statistically different (p = 0.1), thus
excluding any possible gender effect.
Our results therefore demonstrate a lack of association
between CTLA-4 CT60 or +49A/G polymorphisms and pSS
among Caucasians.
Discussion
The results from our first cohort were very close to those from
the study of Downie-Doyle and colleagues [3], with a signifi-
cant association of pSS with the +49A/G*A allele and with the
+49A/G*A allele carriers haplotypes. The association
observed in the first cohort, of two haplotypes bearing the
same allele (CTLA-4 +49A/G*A), was actually more probably
due to the statistical weight of the CTLA-4 +49A/G*A allele
than to a true functional effect of two different haplotypes,
bearing either CTLA-4 CT60*C or CTLA-4 CT60*T alleles,
each having opposite functional effects on CTLA-4 mRNA
expression [2].
In fact, our results suggest a false positive association of
CTLA-4 +49A/G*A allele with pSS in the first cohort of
patients. When data were pooled (cohorts 1 and 2), no signif-
icant association was found with the CTLA-4 +49A/G poly-
morphism in our Caucasian population of patients with pSS.
This was not the consequence of different origin or different
clinico-biological characteristics of the patients from the two
cohorts and could only be the result of a sampling bias.
Indeed, the findings observed in our first cohort of patients, as
those from Downie-Doyle and colleagues [3], were unex-
pected because there are only rare examples of association of
the CTLA-4A/G*A allele with autoimmune diseases [5-7].
Consequently, we might have made premature conclusions if
a replication study had not been performed.
Conclusion
Our study illustrates the necessity to include a large number of
patients in genetic case-control studies. In fact, sampling bias
may partly account for some contradictory results previously
reported for CTLA-4 association studies in autoimmune
diseases.
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